AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG) has been assigned an average rating of “Hold” from the fifteen analysts that are currently covering the company, Marketbeat Ratings reports. Eleven investment analysts have rated the stock with a hold rating and three have given a buy rating to the company. The average 12-month price target among brokers that have covered the stock in the last year is $24.20.
A number of research analysts recently weighed in on the company. BidaskClub raised AMAG Pharmaceuticals from a “hold” rating to a “buy” rating in a report on Friday, April 6th. B. Riley boosted their target price on AMAG Pharmaceuticals from $16.00 to $23.00 and gave the stock a “neutral” rating in a report on Wednesday, March 14th. Jefferies Group lowered AMAG Pharmaceuticals from a “buy” rating to a “hold” rating and decreased their price objective for the company from $21.00 to $20.00 in a report on Monday, March 5th. Piper Jaffray reaffirmed a “hold” rating and issued a $20.00 price objective on shares of AMAG Pharmaceuticals in a report on Thursday, March 1st. Finally, Morgan Stanley upped their price objective on AMAG Pharmaceuticals from $22.00 to $24.00 and gave the company an “overweight” rating in a report on Wednesday, February 28th.
Shares of AMAG stock traded up $0.30 during trading on Thursday, reaching $21.25. 218,485 shares of the company’s stock were exchanged, compared to its average volume of 1,169,370. The company has a current ratio of 1.74, a quick ratio of 1.60 and a debt-to-equity ratio of 0.93. The firm has a market capitalization of $719.28, a PE ratio of -3.68 and a beta of 0.09. AMAG Pharmaceuticals has a twelve month low of $11.93 and a twelve month high of $24.85.
A number of hedge funds and other institutional investors have recently modified their holdings of AMAG. Cambridge Investment Research Advisors Inc. bought a new stake in shares of AMAG Pharmaceuticals during the 4th quarter valued at $161,000. MetLife Investment Advisors LLC bought a new stake in shares of AMAG Pharmaceuticals during the 4th quarter valued at $212,000. Palo Alto Investors LLC lifted its position in shares of AMAG Pharmaceuticals by 1.5% during the 4th quarter. Palo Alto Investors LLC now owns 3,493,220 shares of the specialty pharmaceutical company’s stock valued at $46,285,000 after acquiring an additional 51,987 shares during the period. Two Sigma Securities LLC bought a new stake in shares of AMAG Pharmaceuticals during the 4th quarter valued at $187,000. Finally, Two Sigma Investments LP lifted its position in shares of AMAG Pharmaceuticals by 14.8% during the 4th quarter. Two Sigma Investments LP now owns 35,287 shares of the specialty pharmaceutical company’s stock valued at $468,000 after acquiring an additional 4,542 shares during the period.
AMAG Pharmaceuticals Company Profile
AMAG Pharmaceuticals, Inc, a biopharmaceutical company, manufactures, develops, and commercializes therapeutics for maternal and women's health, anemia management, and cancer supportive care in the United States. It markets Makena, a hydroxyprogesterone caproate injection to reduce the risk of preterm birth in women pregnant with a single baby who have a history of singleton spontaneous preterm birth; Feraheme (ferumoxytol), an intravenous iron replacement therapeutic agent for the treatment of iron deficiency anemia in adult patients who have intolerance to oral iron or have had unsatisfactory response to oral iron, as well as patients who have chronic kidney disease; Intrarosa(prasterone) vaginal insert steroid for the treatment of dyspareunia due to menopause; and MuGard Mucoadhesive Oral Wound Rinse for the management of oral mucocitis/stomatiits and various types of oral wounds.
Receive News & Ratings for AMAG Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AMAG Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.